← Leaderboards
Maria Zoe Kounnas
Neurogenetic Pharmaceuticals, Inc.
$1,374,519
Attributed
$2,749,038
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2015–17$2M$1.5M$1M$500K$0
'15
'16
'17
Funding mix
By agency
NIH$2,749,038 · 1
By mechanism
R01$2,749,038 · 1
Top collaborators
- William T Comer4 shared
Most similar at Neurogenetic Pharmaceuticals, Inc.
Same institution · by research overlap
- William T Comer$4,731,841
Others in their field
Top investigators on “Drug Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Sharon A Nachman · Johns Hopkins University$194,646,762
- Carol Nesel · Westat$147,274,423
- Barbara Driver · Westat, Inc.$103,746,400
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,714,869
Research focus
Drug KineticsAlzheimer&AposAffectAdverse EffectsAmyloid Beta-ProteinAmyloid Beta-Protein PrecursorAlzheimer Disease PreventionAwardBaseAmericanBioimagingBiological MarkersCellular DevelopmentCerebrospinal FluidApplications GrantsClinical EfficacyClinical ResearchCognitiveConfusionCostDementiaBehavioralDoseEffectiveness
Grant awards (4)
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$136,920
R01 · FY2017 · AG · contact PI
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$1,093,421
R01 · FY2016 · AG · contact PI
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$138,884
R01 · FY2016 · AG · contact PI
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$1,379,813
R01 · FY2015 · AG · contact PI